Nurix Therapeutics spent the first half of the fiscal year as a cash-burning protein-degradation shop whose lead BTK degrader still had to prove it could attract a partner large enough to fund a multi-indication late-stage program. That question closed in June when Roche signed a global co-development and co-commercialization pact for bexobrutideg, then cleared Hart-Scott-Rodino review in July. The equity is no longer a standalone platform story. It is a Roche-backed hematology franchise with immunology and neurology expansion rights attached, and the market has already begun to price that shift.
The tension sits in the economics rather than the headline. Roche funds most of global development and splits United States profits evenly, a rare retained-economics structure for a company of this size. In exchange Nurix still carries two-fifths of a development bill that now spans chronic lymphocytic leukemia, other B-cell cancers, chronic spontaneous urticaria, and multiple sclerosis. Cash sat just above $440 million at late May against a November stockpile near $590 million. Collaboration revenue also shrank once last year's Sanofi license extensions rolled off. The European Hematology Association update, with high response rates and multi-month durability in heavily pretreated CLL, is the clinical reason Roche paid up. It is also still early-stage evidence being asked to carry a registrational program.
The next year decides whether the DAYBreak program converts that durability into an accelerated-approval package and whether the immunology work becomes a second valuation pillar before the confirmatory pirtobrutinib head-to-head reads out. Roche is due to deliver a $700 million upfront in the fiscal third quarter. Does that capital plus Roche's antibody portfolio turn bexobrutideg into a multi-indication franchise, or does a crowded BTK field compress the asset back to a single late-line CLL option?